Abstract
Atezolizumab monotherapy has been shown to prolong the overall survival of patients with metastatic non-small-cell lung cancer (NSCLC), who had been previously treated, indicating manageable toxicity. The J-TAIL study aimed to evaluate the long-term effectiveness and safety of atezolizumab monotherapy in patients with unresectable advanced or recurrent NSCLC under real-world settings in Japan. In addition, blood-based biomarker studies were conducted as exploratory research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
